Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial


24 Nov 2018


Poster display - Cocktail


Management of Systemic Therapy Toxicities;  Supportive Care and Symptom Management;  Radiation Oncology

Tumour Site

Breast Cancer


Sepideh Elyasi


Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426


S. Elyasi, H. Karbasforushan, S. Hosseini, A. Fani Pakdel

Author affiliations

  • Clinical Pharmacy, Mashhad University of Medical Sciences, 0000 - Mashhad/IR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1468


Breast cancer is the most common cancer among women. Radiation therapy is one of its main treatment modality. Radiation-induced dermatitis is one of the most common side effects that, in severe cases, may result in treatment discontinuation or delay. Silymarin is a polyphenolic flavonoid extracted from the Silybum marianum that exhibits strong antioxidant and anti-inflammatory activities. The purpose of this study was to investigate the topical silymarin formulation, in prevention of radiodermatitis in patients with breast cancer.


During this randomized, double-blinded, placebo-controlled clinical trial, the effect of silymarin 1% gel was assessed in comparison with placebo formulation, on radiodermatitis occurrence. In this study 40 patients with breast cancer who completed inclusion and exclusion criteria were randomly assigned to receive medicine or placebo formulation on breast twice daily starting at the first day of radiotherapy for 5 weeks. All patients were treated with radiation therapy at a dose of 50 Gy. Radiodermatits severity were assessed weekly based on Radiation therapy oncology group (RTOG) and national cancer institute common terminology for adverse event (CTCAE) criteria for 5 weeks.


Significant difference was observed between the treatment and placebo groups, regarding the NIH CTCAE and RTOG scores at the end of the 4th and 5th weeks (Pvalue<0.05) but not at the end of the first three weeks. The median NIH CTCAE and RTOG scores were significantly lower in silymarin group at the end of the third to fifth weeks (Pvalue<0.05) . The scored increased significantly in both placebo and silymarin groups during radiotherapy, but there were a delay for radiodermatitis development and progression in silymarin group.


Prophylactic administration of silymarin topical formulation could significantly reduce the severity of radiodermatitis and delay its occurrence, in patients with breast cancer after 5 weeks of application.

Editorial acknowledgement

This study is part of a research thesis for a Pharm.D. degree at Mashhad University of Medical Sciences. The authors are thankful for the funding of this study by the Research Council of Mashhad University of Medical Sciences and to Goldaroo Company (Isfahan) for providing the silymarin and placebo gels.

Clinical trial identification


Legal entity responsible for the study

Mashhad University of Medical Sciences.


Mashhad University of Medical Sciences.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.